Skip to results

Expected publication date

Expected publication date

Area of interest

Area of interest

Type (1 selected)

Type

Guidance programme

Showing 301 to 325 of 374

Guidance, NICE advice and quality standards in development
TitleTypeExpected publication date
Ruxolitinib for treating acute graft versus host disease refractory to corticosteroids in people aged 12 and over [ID6377]Technology appraisal guidanceTBC
Ruxolitinib for treating moderate to severe chronic graft-versus-host disease after an allogeneic stem cell transplant in people 28 days to 17 years [ID6427]Technology appraisal guidanceTBC
Ruxolitinib for treating non-segmental vitiligo in people 12 years and over [ID3998]Technology appraisal guidance
Sacituzumab govitecan for treating advanced non-small-cell lung cancer after platinum-based chemotherapy and a PD-1 or PD-L1 inhibitor [ID6375]Technology appraisal guidanceTBC
Sacituzumab govitecan for treating hormone receptor-positive HER2-negative metastatic breast cancer after 2 or more therapies [ID4033]Technology appraisal guidanceTBC
Sacral nerve stimulation for idiopathic chronic non-obstructive urinary retentionInterventional procedures guidanceTBC
Secukinumab for treating enthesitis-related arthritis or juvenile psoriatic arthritis [ID3738]Technology appraisal guidanceTBC
Selective internal radiation therapy with QuiremSpheres for treating unresectable advanced hepatocellular carcinoma (Partial review of TA688) [ID6376]Technology appraisal guidance
Selpercatinib for advanced thyroid cancer with RET alterations that has not been treated with systemic therapy [ID6132]Technology appraisal guidance
Selpercatinib for previously treated RET fusion-positive advanced non-small-cell lung cancer (MA review of TA760) [ID6293]Technology appraisal guidance
Selpercatinib for untreated RET-positive advanced thyroid cancer [ID6183]Technology appraisal guidanceTBC
Sipavibart for preventing COVID 19 [ID6282]Technology appraisal guidance
Sirolimus for treating facial angiofibroma from tuberous sclerosis complex in people 6 years and older [ID6440]Technology appraisal guidanceTBC
Sodium phenylbutyrate–ursodoxicoltaurine for treating amyotrophic lateral sclerosis [ID6246]Technology appraisal guidanceTBC
Somapacitan for treating growth hormone deficiency in children [ID6178]Technology appraisal guidanceTBC
Sotatercept for treating pulmonary arterial hypertension [ID6163]Technology appraisal guidance
Sotorasib for previously treated KRAS G12C mutation-positive advanced non-small-cell lung cancer (MA review of TA781) [ID6287]Technology appraisal guidance
SpaceOAR hydrogel spacer for reducing rectal toxicity during radiotherapy for prostate cancer (Suspended – referred to technology appraisals)Medical technologies guidanceTBC
Sparsentan for treating primary IgA nephropathy [ID6308]Technology appraisal guidance
Spartalizumab with dabrafenib and trametinib for untreated BRAF V600 mutation-positive unresectable or metastatic melanoma [ID1668]Technology appraisal guidance
Spesolimab for preventing generalised pustular psoriasis flares [ID6216]Technology appraisal guidanceTBC
Spesolimab for treating generalised pustular psoriasis flares [ID3963]Technology appraisal guidance
Sugemalimab with chemotherapy for untreated metastatic non-small-cell lung cancer [ID4001]Technology appraisal guidanceTBC
Surgical vessel sealing systems (MT798)Medical technologies guidanceTBC
Suspected sepsis: recognition, diagnosis and early managementNICE guidelineTBC

Results per page

  1. 10
  2. 25
  3. 50
  4. All